|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ELOF1 |
Gene summary for ELOF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ELOF1 | Gene ID | 84337 |
| Gene name | elongation factor 1 | |
| Gene Alias | ELF1 | |
| Cytomap | 19p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P60002 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84337 | ELOF1 | LZE4T | Human | Esophagus | ESCC | 2.46e-07 | 1.50e-01 | 0.0811 |
| 84337 | ELOF1 | LZE5T | Human | Esophagus | ESCC | 6.13e-03 | 1.23e-01 | 0.0514 |
| 84337 | ELOF1 | LZE7T | Human | Esophagus | ESCC | 2.66e-07 | 6.78e-01 | 0.0667 |
| 84337 | ELOF1 | LZE8T | Human | Esophagus | ESCC | 1.34e-03 | 6.26e-02 | 0.067 |
| 84337 | ELOF1 | LZE20T | Human | Esophagus | ESCC | 1.68e-02 | 4.79e-02 | 0.0662 |
| 84337 | ELOF1 | LZE22T | Human | Esophagus | ESCC | 3.25e-04 | 2.28e-01 | 0.068 |
| 84337 | ELOF1 | LZE24T | Human | Esophagus | ESCC | 4.48e-10 | 4.46e-01 | 0.0596 |
| 84337 | ELOF1 | LZE6T | Human | Esophagus | ESCC | 4.77e-02 | 2.51e-01 | 0.0845 |
| 84337 | ELOF1 | P1T-E | Human | Esophagus | ESCC | 2.81e-02 | 5.11e-01 | 0.0875 |
| 84337 | ELOF1 | P2T-E | Human | Esophagus | ESCC | 4.96e-24 | 2.30e-01 | 0.1177 |
| 84337 | ELOF1 | P4T-E | Human | Esophagus | ESCC | 2.04e-28 | 6.86e-01 | 0.1323 |
| 84337 | ELOF1 | P5T-E | Human | Esophagus | ESCC | 5.79e-28 | 5.81e-01 | 0.1327 |
| 84337 | ELOF1 | P8T-E | Human | Esophagus | ESCC | 6.11e-28 | 5.96e-01 | 0.0889 |
| 84337 | ELOF1 | P9T-E | Human | Esophagus | ESCC | 1.85e-16 | 4.09e-01 | 0.1131 |
| 84337 | ELOF1 | P10T-E | Human | Esophagus | ESCC | 5.92e-40 | 6.34e-01 | 0.116 |
| 84337 | ELOF1 | P11T-E | Human | Esophagus | ESCC | 6.82e-12 | 7.17e-01 | 0.1426 |
| 84337 | ELOF1 | P12T-E | Human | Esophagus | ESCC | 1.09e-20 | 3.78e-01 | 0.1122 |
| 84337 | ELOF1 | P15T-E | Human | Esophagus | ESCC | 3.44e-16 | 3.91e-01 | 0.1149 |
| 84337 | ELOF1 | P16T-E | Human | Esophagus | ESCC | 2.17e-24 | 2.28e-01 | 0.1153 |
| 84337 | ELOF1 | P17T-E | Human | Esophagus | ESCC | 7.50e-10 | 6.10e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:000636814 | Esophagus | ESCC | transcription elongation from RNA polymerase II promoter | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
| GO:00480962 | Esophagus | ESCC | chromatin-mediated maintenance of transcription | 11/8552 | 11/18723 | 1.80e-04 | 1.16e-03 | 11 |
| GO:0045815 | Esophagus | ESCC | positive regulation of gene expression, epigenetic | 13/8552 | 17/18723 | 1.00e-02 | 3.42e-02 | 13 |
| GO:00063544 | Liver | Cirrhotic | DNA-templated transcription, elongation | 35/4634 | 91/18723 | 2.56e-03 | 1.53e-02 | 35 |
| GO:00063683 | Liver | Cirrhotic | transcription elongation from RNA polymerase II promoter | 28/4634 | 69/18723 | 2.70e-03 | 1.58e-02 | 28 |
| GO:000635411 | Liver | HCC | DNA-templated transcription, elongation | 64/7958 | 91/18723 | 7.00e-08 | 1.44e-06 | 64 |
| GO:000636811 | Liver | HCC | transcription elongation from RNA polymerase II promoter | 50/7958 | 69/18723 | 4.32e-07 | 7.22e-06 | 50 |
| GO:0040029 | Liver | HCC | regulation of gene expression, epigenetic | 61/7958 | 105/18723 | 9.02e-04 | 5.31e-03 | 61 |
| GO:00063547 | Oral cavity | OSCC | DNA-templated transcription, elongation | 63/7305 | 91/18723 | 4.86e-09 | 1.07e-07 | 63 |
| GO:00063686 | Oral cavity | OSCC | transcription elongation from RNA polymerase II promoter | 48/7305 | 69/18723 | 2.60e-07 | 4.05e-06 | 48 |
| GO:00400294 | Oral cavity | OSCC | regulation of gene expression, epigenetic | 59/7305 | 105/18723 | 2.62e-04 | 1.68e-03 | 59 |
| GO:000635413 | Oral cavity | LP | DNA-templated transcription, elongation | 39/4623 | 91/18723 | 1.08e-04 | 1.31e-03 | 39 |
| GO:000636813 | Oral cavity | LP | transcription elongation from RNA polymerase II promoter | 31/4623 | 69/18723 | 1.92e-04 | 2.11e-03 | 31 |
| GO:004002911 | Oral cavity | LP | regulation of gene expression, epigenetic | 39/4623 | 105/18723 | 3.00e-03 | 2.05e-02 | 39 |
| GO:00480961 | Oral cavity | LP | chromatin-mediated maintenance of transcription | 7/4623 | 11/18723 | 7.01e-03 | 3.96e-02 | 7 |
| GO:000635415 | Skin | cSCC | DNA-templated transcription, elongation | 48/4864 | 91/18723 | 4.58e-08 | 1.19e-06 | 48 |
| GO:000636815 | Skin | cSCC | transcription elongation from RNA polymerase II promoter | 39/4864 | 69/18723 | 7.15e-08 | 1.78e-06 | 39 |
| GO:004002912 | Skin | cSCC | regulation of gene expression, epigenetic | 39/4864 | 105/18723 | 7.56e-03 | 3.53e-02 | 39 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ELOF1 | SNV | Missense_Mutation | c.227A>T | p.Asp76Val | p.D76V | P60002 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A22B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ELOF1 | SNV | Missense_Mutation | novel | c.226G>C | p.Asp76His | p.D76H | P60002 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ELOF1 | SNV | Missense_Mutation | c.229N>A | p.Ala77Thr | p.A77T | P60002 | protein_coding | deleterious(0.02) | probably_damaging(0.975) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ELOF1 | SNV | Missense_Mutation | c.227N>G | p.Asp76Gly | p.D76G | P60002 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ELOF1 | SNV | Missense_Mutation | rs775976345 | c.8N>A | p.Arg3His | p.R3H | P60002 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ELOF1 | SNV | Missense_Mutation | rs11539252 | c.121C>T | p.Arg41Cys | p.R41C | P60002 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ELOF1 | SNV | Missense_Mutation | c.163G>A | p.Glu55Lys | p.E55K | P60002 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ELOF1 | SNV | Missense_Mutation | c.154G>A | p.Val52Met | p.V52M | P60002 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ELOF1 | SNV | Missense_Mutation | c.229G>A | p.Ala77Thr | p.A77T | P60002 | protein_coding | deleterious(0.02) | probably_damaging(0.975) | TCGA-D1-A177-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ELOF1 | SNV | Missense_Mutation | novel | c.14N>G | p.Lys5Arg | p.K5R | P60002 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |